DLBCL-IQs are associated with distinct survival outcomes to BsAb therapy but not CAR T-cell treatment. (A) PCA plot showing sample-wise GSVA enrichment scores for DLBCL biopsies from patients treated with mosunetuzumab (N = 74). (B) PFS for patients assigned to “hot” or “cold” DLBCL immune clusters and treated with mosunetuzumab (top) and forest plot showing hazard ratio of the association between PC1 score and PFS (bottom). (C) PFS for patients assigned to GCB hot and GCB cold DLBCL-IQs and treated with mosunetuzumab. Log-rank test with P value displayed. (D) PCA plot showing sample-wise GSVA enrichment scores for DLBCL biopsies from patients treated with CD19 CAR T-cell therapy (Stanford, N = 51). (E) EFS for patients assigned to “hot” or “cold” DLBCL immune clusters and treated with CAR T-cell therapy (top) and forest plot showing hazard ratio of the association between PC1 score and PFS (bottom). (F) EFS for patients assigned to each DLBCL-IQ and treated with CAR T-cell therapy. Log-rank test with P value displayed.